Zobrazeno 1 - 10
of 369
pro vyhledávání: '"Stephen L, Chan"'
Autor:
Landon L. Chan, Stephen L. Chan
Publikováno v:
Клинический разбор в общей медицине, Vol 5, Iss 7, Pp 24-36 (2024)
Emergence of multi-targeted kinase inhibitors (MTIs) and immune checkpoint inhibitors (ICI) have changed the landscape of management in hepatocellular carcinoma (HCC). Combination therapy involving ICI has superseded sorafenib as the first-line treat
Externí odkaz:
https://doaj.org/article/6018f6404fd44328a5aec940740119bd
Autor:
Wei Kang, Caige Huang, Vincent K. C. Yan, Yue Wei, Jessica J. P. Shami, Silvia T. H. Li, Yu Yang, Xuxiao Ye, Junhan Tang, Shing Fung Lee, Victor H. F. Lee, Stephen L. Chan, Aya El Helali, Ka On Lam, Roger K. C. Ngan, Ian C. K. Wong, Esther W. Chan
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-11 (2024)
Abstract Given the existing uncertainty regarding the effectiveness and safety of switching from low-molecular-weight heparin (LMWH) to direct oral anticoagulants (DOACs) in patients with cancer-associated venous thrombosis (CAT), we conducted a comp
Externí odkaz:
https://doaj.org/article/3266406845e141328a147fcdb5358cb5
Autor:
Armando Santoro, Eric Assenat, Thomas Yau, Jean-Pierre Delord, Michela Maur, Jennifer Knox, Stephane Cattan, Kyung-Hun Lee, Gianluca Del Conte, Christoph Springfeld, Elisa Leo, Alexandros Xyrafas, Lauren Fairchild, Feby Mardjuadi, Stephen L. Chan
Publikováno v:
JHEP Reports, Vol 6, Iss 4, Pp 101021- (2024)
Background & aims: This phase Ib/II trial evaluated the safety and efficacy of capmatinib in combination with spartalizumab or spartalizumab alone in patients with advanced hepatocellular carcinoma (HCC). Methods: Eligible patients who had progressed
Externí odkaz:
https://doaj.org/article/9e42ee62344d4ac28b99c8e6f48601dc
Autor:
Landon L. Chan, Stephen L. Chan
Publikováno v:
Clinical and Molecular Hepatology, Vol 29, Iss 4, Pp 909-923 (2023)
Emergence of multi-targeted kinase inhibitors (MTIs) and immune checkpoint inhibitors (ICI) have changed the landscape of management in hepatocellular carcinoma (HCC). Combination therapy involving ICI has superseded sorafenib as the first-line treat
Externí odkaz:
https://doaj.org/article/8d62e67bb0b442e086f1983cd638e24c
Autor:
Landon L. Chan, Stephen L. Chan
Publikováno v:
Clinical and Molecular Hepatology, Vol 29, Iss 2, Pp 345-348 (2023)
Externí odkaz:
https://doaj.org/article/7b9c3ac908c34b28b9adc4f5dc287112
Autor:
Kyunghye Bang, Andrea Casadei‐Gardini, Changhoon Yoo, Massimo Iavarone, Min‐Hee Ryu, Sook Ryun Park, Hyung‐Don Kim, Young‐In Yoon, Dong‐Hwan Jung, Gil‐Chun Park, Chul‐Soo Ahn, Deok‐Bog Moon, Shin Hwang, Ki‐Hun Kim, Gi‐Won Song, Chiara Mazzarelli, Eleonora Alimenti, Stephen L. Chan, Massimo De Giorgio, Baek‐Yeol Ryoo, Sung‐Gyu Lee
Publikováno v:
Cancer Medicine, Vol 12, Iss 3, Pp 2572-2579 (2023)
Abstract Introduction Lenvatinib is approved for the treatment of patients with metastatic or recurrent hepatocellular carcinoma (HCC); however, clinical outcomes of lenvatinib therapy in patients with post‐liver transplantation (LT) HCC recurrence
Externí odkaz:
https://doaj.org/article/3a4d488f1ccf435b83b8ccfb949c2e89
Autor:
Stephen L. Chan, Martin Schuler, Yoon-Koo Kang, Chia-Jui Yen, Julien Edeline, Su Pin Choo, Chia-Chi Lin, Takuji Okusaka, Karl-Heinz Weiss, Teresa Macarulla, Stéphane Cattan, Jean-Frederic Blanc, Kyung-Hun Lee, Michela Maur, Shubham Pant, Masatoshi Kudo, Eric Assenat, Andrew X. Zhu, Thomas Yau, Ho Yeong Lim, Jordi Bruix, Andreas Geier, Carmen Guillén-Ponce, Angelica Fasolo, Richard S. Finn, Jia Fan, Arndt Vogel, Shukui Qin, Markus Riester, Vasiliki Katsanou, Monica Chaudhari, Tomoyuki Kakizume, Yi Gu, Diana Graus Porta, Andrea Myers, Jean-Pierre Delord
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 41, Iss 1, Pp 1-19 (2022)
Abstract Background Deregulation of FGF19-FGFR4 signaling is found in several cancers, including hepatocellular carcinoma (HCC), nominating it for therapeutic targeting. FGF401 is a potent, selective FGFR4 inhibitor with antitumor activity in preclin
Externí odkaz:
https://doaj.org/article/1a80d93b46254b83bfdf5d4c0de1a368
Autor:
Masatoshi Kudo, Tomoko Aoki, Kazuomi Ueshima, Kaoru Tsuchiya, Masahiro Morita, Hirokazu Chishina, Masahiro Takita, Satoru Hagiwara, Yasunori Minami, Hiroshi Ida, Naoshi Nishida, Chikara Ogawa, Tetsu Tomonari, Noriaki Nakamura, Hidekatsu Kuroda, Atsushi Takebe, Yoshifumi Takeyama, Masaaki Hidaka, Susumu Eguchi, Stephen L Chan, Masayuki Kurosaki, Namiki Izumi
Publikováno v:
Liver Cancer (2023)
Introduction: Atezolizumab plus bevacizumab therapy is extremely effective in the treatment of intermediate-stage hepatocellular carcinoma (HCC), with a response rate of 44%, as reported in the IMbrave150 trial. When tumor shrinkage is obtained, achi
Externí odkaz:
https://doaj.org/article/332e0f13cacf47a9aac3a9b2a4a83f4a
Autor:
Arndt Vogel, Catherine Frenette, Max Sung, Bruno Daniele, Ari Baron, Stephen L. Chan, Jean Frédéric Blanc, Toshiyuki Tamai, Min Ren, Howard J. Lim, Daniel H. Palmer, Yuko Takami, Masatoshi Kudo
Publikováno v:
Liver Cancer, Pp 1-12 (2021)
Introduction: Baseline liver function among patients starting treatment for unresectable hepatocellular carcinoma (uHCC) impacts survival and could impact efficacy outcomes and safety profiles of treatments. This post hoc analysis of the phase 3 REFL
Externí odkaz:
https://doaj.org/article/140e47299e9d4fc9a6db9a3d2e1db1df
Publikováno v:
Liver Cancer, Pp 1-1 (2023)
Background The incidence of intrahepatic cholangiocarcinoma (IHCCA) is rising around the world. The disease is becoming a major global health issue. Conventionally, most patients with cholangiocarcinoma present with advanced disease and systemic ther
Externí odkaz:
https://doaj.org/article/f6244b003b5e423abb3f32c392c179f0